CLDN18.2

Creative Biolabs furnishes top-grade and all-inclusive recombinant antibodies specific to CLDN18.2. These antibodies are custom-tailored to fulfill the demands of biomedical researchers and institutions. With painstaking development, they ensure reliable functionality, thereby assisting researchers in advancing cancer research and immunotherapy endeavors.

CLDN18.2: A Critical Protein Target for Cancer Immunotherapy

CLDN18.2, which is a tight junction protein, is mainly found in the stomach and several cancer types such as gastric and pancreatic cancers. As part of the Claudin family, it has a crucial function in preserving the integrity of cell-cell connections and modulating epithelial cell function. The fact that it is overexpressed in malignant cells has turned CLDN18.2 into an attractive target for cancer immunotherapy. Antibodies directed against CLDN18.2 are under investigation as prospective treatments, particularly in targeted therapies like antibody-drug conjugates (ADCs), to selectively eradicate cancer cells while reducing harm to healthy tissues.

Alternative Names

Claudin 18.2

Anti-CLDN18.2 rAb Products

The state-of-the-art anti-CLDN18.2 recombinant antibodies we offer are meticulously engineered to reinforce and expedite investigations focusing on the development of CLDN18.2-targeted drugs. By supplying high-caliber and trustworthy products, we strive to drive scientific advancement and contribute to the discovery of novel therapies related to CLDN18.2, with a particular emphasis on cancer treatment.

Creative Quality Control

To maintain the highest possible antibody quality benchmarks, we have instituted a comprehensive quality management framework. This framework secures the consistency and reliability of our products, allowing researchers to execute their work with confidence and competence.

Customer Reviews

Excellent

L**m
Human Anti-CLDN18.2 Recombinant Antibody (Cat#: HPAB-AP289-YC)

For my research endeavor, the human anti-CLDN18.2 recombinant antibody was deployed to probe into the CLDN18.2 expression levels within cancerous tissues. When ELISA was applied, the antibody manifested an outstanding level of specificity, accurately detecting CLDN18.2 present on the tumor cell surfaces. The results obtained were not only consistent but also highly reliable, thereby validating the suitability of this antibody for cancer research with a specific focus.

16/Feb/2024

Excellent

E**an
Mouse Anti-CLDN18.2 Recombinant Antibody (Cat#: HPAB-0120-YJ)

I incorporated the Mouse Anti-CLDN18.2 Recombinant Antibody in my study on CLDN18.2 expression in cancer, specifically for Western blotting (WB) and immunohistochemistry (IHC). The results turned out to be highly satisfactory. The antibody demonstrated a remarkable ability to identify CLDN18.2 in tissue samples, owing to its accurate targeting and stable performance. This provided reliable data that deepened my understanding of the role of CLDN18.2 in cancer.

28/Oct/2022

rAb Production

A rich reservoir of experience is held by us in optimizing key processes such as expression vector design, transfected cell line screening, and antibody purification. Our services, which are comprehensive in nature, cover the entire spectrum from gene synthesis right through to antibody production, ensuring reliable and efficient solutions are at the disposal of biomedical researchers.

Featured Anti-CLDN18.2 Recombinant Antibody Production Platforms
Fig.3 Milligram-scale recombinant antibody production.

Fig.4 Gram-scale recombinant antibody production.

rAb Modalities

Creative Biolabs devotes itself to furnishing researchers with high-quality recombinant antibodies in diverse formats. These formats, including full-length antibodies, Fab fragments, scFv, scFv-Fc and so on, are customized to meet a wide array of research needs. The variety ensures flexibility and broad applicability in experimental operations.

Fig.5 Full Length Anti-CLDN18.2 Recombinant Antibody Production and Modalities.

Drug Information Targeting CLDN18.2

Table 1. Therapeutic approaches targeting CLDN18.2 in clinical development.

If you would like further details about our anti-CLDN18.2 recombinant antibody products, feel free to contact us. We look forward to assisting you and exploring the potential for a productive and mutually beneficial partnership.